CGON · Insider Trading
CG Oncology, Inc. Common stock
Every open-market purchase and sale reported by CGON officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Leonard E Post | Director | MIXED | — | −$72.38K |
| 2026-08-18 | Leonard E Post | Director | MIXED | — | −$73.94K |
| 2026-07-17 | Leonard E Post | Director | MIXED | — | −$70.57K |
| 2026-07-14 | James Mulay | Director | MIXED | — | −$1.17M |
| 2026-06-29 | Brian Guan-Chyun Liu | Director | Buy | +371,085 | +$24.81M |
| 2026-06-25 | Leonard E Post | Director | MIXED | — | −$347.00K |
| 2026-06-23 | Leonard E Post | Director | MIXED | — | −$322.00K |
| 2026-06-16 | James Mulay | Director | MIXED | — | −$99.15K |
| 2026-06-05 | James Mulay | Director | A | +9,354 deriv. | — |
| 2026-06-05 | Susan E Graf | Director | A | +9,354 deriv. | — |
| 2026-06-05 | Leonard E Post | Director | MIXED | — | −$53.90K |
| 2026-06-05 | Victor Edward Tong Jr | Director | A | +9,354 deriv. | — |
| 2026-06-05 | Brian Guan-Chyun Liu | Director | A | +9,354 deriv. | — |
| 2026-06-05 | Christina Rossi | Director | A | +9,354 deriv. | — |
| 2026-04-20 | James Mulay | Director | MIXED | — | −$567.53K |
| 2026-04-16 | Joshua F. Patterson | See Remarks | A | +45,266 deriv. | — |
| 2026-04-16 | Vijay Kasturi | Chief Medical Officer | A | +79,216 deriv. | — |
| 2026-04-16 | Arthur Kuan | Chief Executive Officer | A | +271,600 deriv. | — |
| 2026-04-16 | James M. Detore | Chief Financial Officer | A | +90,574 deriv. | — |
| 2026-04-16 | Ambaw Bellete | President and COO | A | +107,508 deriv. | — |
| 2026-03-17 | James Mulay | Director | MIXED | — | −$105.79K |
| 2026-03-13 | Arthur Kuan | Chief Executive Officer | MIXED | +62,765 | +$36 |
| 2026-03-06 | Arthur Kuan | Chief Executive Officer | MIXED | +100,000 | +$56 |
| 2026-01-13 | James Mulay | Director | MIXED | — | −$450.28K |
| 2025-11-26 | Christina Rossi | Director | A | +20,889 deriv. | — |
| 2025-11-18 | Leonard E Post | Director | MIXED | — | −$40.83K |
| 2025-10-15 | Leonard E Post | Director | MIXED | — | −$42.65K |
| 2025-10-10 | James Mulay | Director | MIXED | — | −$237.71K |
| 2025-10-01 | Leonard E Post | Director | MIXED | — | −$197.45K |
| 2025-09-30 | James Mulay | Director | MIXED | — | −$476.65K |
| 2025-09-22 | James Mulay | Director | MIXED | — | −$843.62K |
| 2025-09-16 | Leonard E Post | Director | MIXED | — | −$34.50K |
| 2025-09-15 | Brian Guan-Chyun Liu | Director | Buy | +1,515,151 | +$50.00M |
| 2025-09-08 | James Mulay | Director | MIXED | — | −$835.59K |
| 2025-09-04 | Hong Fang Song | Director | Sell | −100,000 | −$2.78M |
| 2025-09-04 | Leonard E Post | Director | MIXED | — | −$27.40K |
| 2025-07-18 | Leonard E Post | Director | MIXED | — | −$54.80K |
| 2025-06-06 | Hong Fang Song | Director | A | +24,165 deriv. | — |
| 2025-06-06 | James Mulay | Director | A | +24,165 deriv. | — |
| 2025-06-06 | Leonard E Post | Director | A | +24,165 deriv. | — |
| 2025-06-06 | Victor Edward Tong Jr | Director | A | −24,165 deriv. | — |
| 2025-06-06 | Susan E Graf | Director | A | +24,165 deriv. | — |
| 2025-06-06 | Brian Guan-Chyun Liu | Director | A | +24,165 deriv. | — |
| 2025-05-22 | Leonard E Post | Director | MIXED | — | −$27.40K |
| 2025-04-29 | Leonard E Post | Director | MIXED | — | −$30.16K |
| 2025-04-16 | Vijay Kasturi | Chief Medical Officer | A | +203,868 deriv. | — |
| 2025-04-16 | Ambaw Bellete | President and COO | A | +284,816 deriv. | — |
| 2025-04-16 | Arthur Kuan | Chief Executive Officer | A | +527,660 deriv. | — |
| 2025-04-16 | Corleen M. Roche | CFO | A | +143,907 deriv. | — |
| 2025-04-16 | Joshua F. Patterson | See Remarks | A | +119,922 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Hong Fang Song | Director | 3,517,959 | $210.55M |
| Brian Guan-Chyun Liu | Director | 1,886,236 | $112.89M |
| Arthur Kuan | Chief Executive Officer | 200,763 | $12.02M |
| Corleen M. Roche | CFO | 2,000 | $119.70K |
| Vijay Kasturi | Chief Medical Officer | 1,315 | $78.70K |
| Leonard E Post | Director | 1,000 | $59.85K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CGON quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.